<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116556</url>
  </required_header>
  <id_info>
    <org_study_id>RIFA-AAH.</org_study_id>
    <nct_id>NCT02116556</nct_id>
  </id_info>
  <brief_title>Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis</brief_title>
  <acronym>RIFA-AAH</acronym>
  <official_title>Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute alcoholic hepatitis (AAH) is a serious condition and one of the most frequent causes of
      Acute-on-Chronic Liver Failure. The current standard therapy (corticosteroids) is theme of
      debate and unsatisfactory in many patients (year mortality: 30%). One of the main causes of
      death is bacterial infections, which affect 40-50% of patients at 90 days. Intestinal
      decontamination with rifaximin (a nonabsorbable antibiotic) reduces endotoxemia, improves
      liver function and reduces the complications of decompensated alcoholic cirrhosis.

      The Hypothesis/Objective: To assess whether oral decontamination with rifaximin prevents the
      development of infections associated with AAH and analyze its consequences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Open multicenter comparative study. A cohort (n = 66) will receive rifaximin (1200 mg
      / d) for 90 days. Results will be compared with those of a cohort of AAH prospectively
      included in an observational study. Both groups with a uniform treatment protocol (which
      includes the administration of corticosteroids and standardized treatment for complications
      of liver failure). Patients will be monitorized until hospital discharge and a follow-up
      visit at 7, 30, 45, 60 and 90 days will be performed.

      Endpoints:

        1. Primary endpoint: Bacterial infections after 90 days.

        2. Secondary endpoints: :

      2.1. Liver function tests 2.2. Levels of endotoxemia 2.3. Complications of liver cirrhosis.
      2.4. Survival
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of bacterial infections</measure>
    <time_frame>90 days</time_frame>
    <description>Development of any bacterial infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Decompensations of Liver Cirrhosis</measure>
    <time_frame>90 days</time_frame>
    <description>Development of any liver cirrhosis decompensations
Hepatic Encephalopathy
Acute Kidney Injury (including Hepatorenal Syndrome)
Acute variceal bleeding
Ascites
Death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Endotoxemia serum levels</measure>
    <time_frame>90 days</time_frame>
    <description>Measurement of serum changes in endotoxemia levels during the rifaximin treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone PO 40mg/day for 30 days plus standard supportive care measurements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone plus Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone PO 40mg/day for 30 days plus Rifaximin PO 1200 mg/day for 90 days plus standard supportive care measurements</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.</description>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_label>Prednisone plus Rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin PO 1200 mg/day for 90 days</description>
    <arm_group_label>Prednisone plus Rifaximin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 and &lt;70 years of age.

          -  Active alcohol abuse and excessive alcohol consumption prior to admission defined as &gt;
             50 g per day for men and&gt; 40 g per day for women.

          -  Jaundice (Bilirubin &gt;2 mg/dl) for no more than 3 months.

          -  Clinical suspicion of Alcoholic Hepatitis with a modified Maddrey's Discriminant
             Function &gt; 32 points.

        Exclusion Criteria:

          -  Hypersensitivity to Rifaximin

          -  Advanced Chronic or Terminal illness. Advanced Chronic illness will be defined as: all
             conditions evolved into a clinical stage to limit the patient's functional status (eg,
             heart failure NYHA&gt; II, COPD PCO2&gt; 50 mmHg or PO2 &lt;60 mmHg, stroke or other disabling
             neurological disease, disabling or uncontrolled oncological conditions, etc ...).

        Terminal illness will be defined as any clinical conditions with a survival expectancy less
        than 3 months

          -  Hepatocellular carcinoma (previously diagnosed) beyond Milan's criteria.

          -  Complete portal vein thrombosis (previously diagnosed).

          -  Autoimmune liver disease.

          -  Hepatitis B and C and HIV infection (anti-HCV, surface HBV antigen and anti-HIV
             positive).

          -  Pregnancy or nursing.

          -  Use of Rifaximin during the previous 2 months.

          -  Treatment with Pentoxifylline.

          -  Lack of informed consent.

        Removal criteria:

          -  Lack of histological confirmation of Alcoholic Hepatitis during the first 7 days after
             inclusion.

        Because there are no non-diagnostic tools to diagnose alcoholic hepatitis, histological
        confirmation is required in all patients (preferably through a transjugular biopsy):
        alcoholic hepatitis will be diagnosed on the presence of the following histologic features:

        Hepatocellular damage (eg, hepatocyte ballooning and presence of Mallory-Denk bodies).

        Inflammatory infiltrate (predominantly polymorphonuclear cells). Pericellular or sinusoidal
        fibrosis.

          -  Hepatocellular carcinoma beyond Milan's criteria diagnosed during the first 7 days
             after inclusion.

          -  Complete portal vein thrombosis diagnosed during the first 7 days after inclusion.

          -  Protocol violation.

          -  Severe adverse event directly related with Rifaximin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Vargas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal Medicine Service. Vall d'Hebron Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholic Hepatitis</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Acute-on-Chronic Liver Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

